ProCE Banner Activity

CaboPoint: Phase II Trial of Second-line Cabozantinib Following Checkpoint Inhibitor–Based Combination Therapy for Advanced RCC

Capsule Summary
Conference Coverage

First interim analysis of CaboPoint phase II study suggests cabozantinib is effective after first-line checkpoint inhibitor combination therapy in patients with advanced RCC.

Released: February 24, 2023

Expiration: February 23, 2024


Provided by

ProCE Banner


This activity is supported by educational grants from:

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.